Clinical Trials
49 trialsNCT06667908 2026-06-05
CONVERGE
Johnson & Johnson Enterprise Innovation Inc.
Phase 2 Recruiting
NCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT02519348 2026-06-03
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07459634 2026-05-27
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT05061550 2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2 Recruiting
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT05374603 2026-05-14
SOUND
AstraZeneca
Phase 2 Active not recruiting
NCT04379596 2026-05-13
DG-03
AstraZeneca
Phase 2 Recruiting
NCT07081633 2026-05-12
TREMENDOUS-2
AstraZeneca
Phase 2 Active not recruiting
NCT03459846 2026-05-11
BAYOU
AstraZeneca
Phase 2 Active not recruiting
NCT03775486 2026-05-01
ORION
AstraZeneca
Phase 2 Active not recruiting
NCT04999969 2026-04-30
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
NCT04745689 2026-04-24
TAZMAN
AstraZeneca
Phase 2 Active not recruiting
NCT05925530 2026-04-16
MDT-BRIDGE
AstraZeneca
Phase 2 Active not recruiting
NCT02087423 2026-04-06
ATLANTIC
AstraZeneca
Phase 2 Completed
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Phase 2 Recruiting
NCT06008093 2026-03-30
TRITON
AstraZeneca
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT04644289 2025-10-03
WoO
AGO Research GmbH
Phase 2 Recruiting
NCT05061134 2025-07-31
MONETTE
AstraZeneca
Phase 2 Active not recruiting
NCT05498155 2025-06-10
OlympiaN
AstraZeneca
Phase 2 Active not recruiting
NCT05742607 2025-05-16
MATISSE
Innate Pharma
Phase 2 Recruiting
NCT03944772 2025-01-30
ORCHARD
AstraZeneca
Phase 2 Active not recruiting
NCT04249362 2025-01-10
DUART
AstraZeneca
Phase 2 Completed
NCT03822351 2024-10-08
COAST
MedImmune LLC
Phase 2 Completed
NCT03693300 2024-06-18
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT04089553 2024-04-16
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
AstraZeneca
Phase 2 Completed
NCT03840902 2024-01-16
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 2 Terminated
NCT02879617 2024-01-05
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
Academic Thoracic Oncology Medical Investigators Consortium
Phase 2 Completed
NCT02527434 2023-11-15
Study of Tremelimumab in Patients With Advanced Solid Tumors
AstraZeneca
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT02775903 2023-02-28
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
Phase 2 Completed
NCT02807454 2023-02-21
FUSIONMM-003
Celgene
Phase 2 Terminated
NCT03794544 2022-02-24
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
MedImmune LLC
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT02207530 2020-09-29
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT02319044 2020-09-29
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT04145193 2020-09-21
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC
Phase 2 Withdrawn
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03419559 2019-04-16
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 2 Withdrawn
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed
NCT02673814 2016-08-01
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn